CRISIL upgrades Sahajanand Medical Technologies to CRISIL A
Sahajanand Medical Technologies (NSE: SMT) said CRISIL has upgraded its credit rating to CRISIL A. The company is valued at about ₹4,939 crore.
What happened
Sahajanand Medical Technologies (NSE: SMT) informed the stock exchanges on 4 November 2026 at 03:58 PM that CRISIL has upgraded its credit rating to CRISIL A.
Company snapshot
Sahajanand Medical Technologies is a small-cap company, with a market value of about ₹4,939 crore.
The stock last traded at ₹485.9, against a 52-week range of ₹451.3–₹499.9 (2.8% below the high).
Promoters held 36.20% at the end of Q3 FY27; 0.01% of promoter shares were pledged. Foreign institutions owned 35.10% and domestic institutions 11.83%.
What history shows
BCEIE has no earlier credit rating filing from this company on record since May 2026.
Market-wide, 1,405 credit rating filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 46% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Whether other agencies take a similar view on the company's credit.
- 5 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Sahajanand Medical Technologies Shares List at 8% Premium on NSE
- Sahajanand Medical Technologies IPO: GMP, Price, Apply or Avoid
- Sahajanand Medical Technologies Ltd. Peer Comparison – Compare with Others
- Sahajanand Medical Technologies shares debut at up to 8% premium over IPO price
- Sahajanand Medical Technologies IPO makes debut with 7.9% premium at ₹371 apiece on the NSE
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.